REGENXBIO Inc. (NASDAQ:RGNX) Short Interest Up 18.4% in December

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 6,230,000 shares, a growth of 18.4% from the November 30th total of 5,260,000 shares. Based on an average daily trading volume, of 1,020,000 shares, the short-interest ratio is presently 6.1 days.

Insiders Place Their Bets

In other news, Director Argeris N. Karabelas sold 10,000 shares of the business's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the transaction, the director now owns 11,286 shares of the company's stock, valued at approximately $114,101.46. The trade was a 46.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.13% of the stock is currently owned by company insiders.

Institutional Trading of REGENXBIO

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Redmile Group LLC lifted its position in shares of REGENXBIO by 7.1% during the third quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company's stock worth $51,327,000 after purchasing an additional 323,100 shares during the last quarter. Integral Health Asset Management LLC lifted its holdings in REGENXBIO by 25.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company's stock valued at $11,115,000 after buying an additional 190,000 shares in the last quarter. Millennium Management LLC lifted its holdings in REGENXBIO by 84.8% during the 2nd quarter. Millennium Management LLC now owns 306,487 shares of the biotechnology company's stock valued at $3,586,000 after buying an additional 140,666 shares in the last quarter. Squarepoint Ops LLC boosted its position in REGENXBIO by 630.9% in the 2nd quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company's stock valued at $1,711,000 after buying an additional 126,249 shares during the period. Finally, Cubist Systematic Strategies LLC grew its stake in REGENXBIO by 73.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 188,235 shares of the biotechnology company's stock worth $2,202,000 after acquiring an additional 79,655 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on RGNX. StockNews.com upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, September 20th. Morgan Stanley reiterated an "overweight" rating and issued a $22.00 target price on shares of REGENXBIO in a research report on Friday, November 15th. Royal Bank of Canada restated an "outperform" rating and set a $35.00 price target on shares of REGENXBIO in a report on Wednesday, December 11th. HC Wainwright decreased their price objective on REGENXBIO from $40.00 to $36.00 and set a "buy" rating on the stock in a report on Thursday, November 21st. Finally, Chardan Capital reiterated a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.27.

REGENXBIO Price Performance

Shares of RGNX traded down $0.18 during midday trading on Monday, hitting $7.23. The stock had a trading volume of 1,757,332 shares, compared to its average volume of 721,488. The stock's 50 day moving average is $9.27 and its 200 day moving average is $10.93. The firm has a market cap of $358.21 million, a PE ratio of -1.44 and a beta of 1.24. REGENXBIO has a 1 year low of $7.15 and a 1 year high of $28.80.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.